Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

Korro remains on track to submit a regulatory filing for a first-in-human study of KRRO-110 in AATD patients anticipated in the second half of 2024. CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for ...